Truist Securities Maintains Hold on Fresenius Medical Care, Lowers Price Target to $24
Portfolio Pulse from Benzinga Newsdesk
Truist Securities analyst David Macdonald maintains a 'Hold' rating on Fresenius Medical Care (NYSE:FMS) and lowers the price target from $28 to $24.
October 11, 2023 | 7:55 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Truist Securities has maintained a 'Hold' rating on Fresenius Medical Care and lowered the price target from $28 to $24.
The lowering of the price target by Truist Securities from $28 to $24 indicates a potential decrease in the stock's value. This could lead to a negative short-term impact on Fresenius Medical Care's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100